Marco Boeri

List of Publications by Year
in descending order

46 papers	843 citations	430874 18 h-index	552781 26 g-index
47 all docs	47 docs citations	47 times ranked	1045 citing authors

#	Article	IF	Citations
1	Exploring determinants of psoriasis patientsâ€™ treatment choices: a discrete-choice experiment study in the United States and Germany. Journal of Dermatological Treatment, 2022, 33, 1511-1520.	2.2	4
2	A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom. Pharmacoeconomics, 2022, 40, 65-76.	3.3	8
3	Exploring patient preference heterogeneity for pharmacological treatments for chronic pain: A latent class analysis. European Journal of Pain, 2022, 26, 648-667.	2.8	7
4	Implementation of personalised medicine policies in mental healthcare: results from a stated preference study in the UK. BJPsych Open, 2022, 8, e40.	0.7	2
5	Relative importance of clinical outcomes and safety risks of antiseizure medication monotherapy for patients and physicians: Discrete choice experiment eliciting preferences in realâ€world study "VOTE". Epilepsia, 2022, 63, 451-462.	5.1	7
6	Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report. Value in Health, 2022, 25, 685-694.	0.3	23
7	Matching and weighting in stated preferences for health care. Journal of Choice Modelling, 2022, 44, 100367.	2.3	1
8	Impact of clinical and demographic characteristics on patient preferences for psoriasis treatment features: Results from a discrete-choice experiment in a multicountry study. Journal of Dermatological Treatment, 2021, , 1-8.	2.2	3
9	Long-Acting Injection and Implant Preferences and Trade-Offs for HIV Prevention Among South African Male Youth. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 928-936.	2.1	9
10	Discrete choice experiment (DCE) to quantify the influence of trial features on the decision to participate in cystic fibrosis (CF) clinical trials. BMJ Open, 2021, 11, e045803.	1.9	3
11	The Impact of the Risk Functional Form Assumptions on Maximum Acceptable Risk Measures. Patient, 2021, 14, 827-836.	2.7	6
12	CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma: physician preferences trading off benefits, risksÂand time to infusion. Future Oncology, 2021, 17, 4697-4709.	2.4	2
13	Mobilising the Next Generation of Stated-Preference Studies: the Association of Access Device with Choice Behaviour and Data Quality. Patient, 2021, 14, 55-63.	2.7	7
14	Efficacy is Not Everything: Eliciting Womenâ€™s Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment. AIDS and Behavior, 2020, 24, 1443-1451.	2.7	22
15	Public preferences for multiple dimensions of bird biodiversity at the coast: insights for the cultural ecosystem services framework. Estuarine, Coastal and Shelf Science, 2020, 235, 106571.	2.1	9
16	Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment. Osteoarthritis and Cartilage, 2020, 28, 1202-1213.	1.3	31
17	Patient Preferences in Surveillance: Findings From a Discrete Choice Experiment in the â€œMy Follow-Upâ€ Study. Value in Health, 2020, 23, 1373-1383.	0.3	1
18	Preferences for longâ€acting Preâ€Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment. Journal of the International AIDS Society, 2020, 23, e25528.	3.0	49

#	Article	IF	Citations
19	Modeling Heterogeneity in Patients' Preferences for Psoriasis Treatments in a Multicountry Study: A Comparison Between Random-Parameters Logit and Latent Class Approaches. Pharmacoeconomics, 2020, 38, 593-606.	3.3	17
20	Patient Preferences for Biologic and Biosimilar Osteoporosis Treatments in Colombia . Patient Preference and Adherence, 2020, Volume 14, 1049-1064.	1.8	1
21	Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow‐up question. Health Economics (United Kingdom), 2020, 29, 1307-1315.	1.7	3
22	<p>Patient and physician preferences for ulcerative colitis treatments in the United States</p>. Clinical and Experimental Gastroenterology, 2019, Volume 12, 263-278.	2.3	27
23	From drug-delivery device to disease management tool: a study of preferences for enhanced features in next-generation self-injection devices . Patient Preference and Adherence, 2019, Volume 13, 1093-1110.	1.8	8
24	Young Women's Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 394-403.	2.1	69
25	Physician-Specific Maximum Acceptable Risk in Personalized Medicine: Implications for Medical Decision Making. Medical Decision Making, 2018, 38, 593-600.	2.4	4
26	Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment. Pharmacoeconomics, 2018, 36, 973-986.	3.3	15
27	Behavioural patterns in Mediterranean-style drinking: Generation Y preferences in alcoholic beverage consumption. Journal of Behavioral and Experimental Economics, 2018, 75, 117-125.	1.2	22
28	The Influence of Genotype Information on Psychiatrists' Treatment Recommendations: More Experienced Clinicians Know Better What to Ignore. Value in Health, 2017, 20, 126-131.	0.3	6
29	The importance of regret minimization in the choice for renewable energy programmes: Evidence from a discrete choice experiment. Energy Economics, 2017, 63, 253-260.	12.1	37
30	Patients' priorities in selecting chronic lymphocytic leukemia treatments. Blood Advances, 2017, 1, 2176-2185.	5.2	26
31	The STARTEC Decision Support Tool for Better Tradeoffs between Food Safety, Quality, Nutrition, and Costs in Production of Advanced Ready-to-Eat Foods. BioMed Research International, 2017, 2017, 1-13.	1.9	18
32	How Do Psychiatrists Apply the Minimum Clinically Important Difference to Assess Patient Responses to Treatment?. MDM Policy and Practice, 2016, 1, 238146831667885.	0.9	2
33	Stated preference methods and landscape ecology indicators: An example of transdisciplinarity in landscape economic valuation. Ecological Economics, 2016, 127, 11-22.	5.7	22
34	Food fraud and consumers' choices in the wake of the horsemeat scandal. British Food Journal, 2016, 118, 1898-1913.	2.9	42
35	Learning, fatigue and preference formation in discrete choice experiments. Journal of Economic Behavior and Organization, 2015, 119, 345-363.	2.0	42
36	Addressing inequalities in physical activity participation: Implications for public health policy and practice. Preventive Medicine, 2015, 72, 64-69.	3.4	27

#	Article	IF	Citations
37	Regret minimisation and utility maximisation in a freight transport context. Transportmetrica A: Transport Science, 2014, 10, 548-560.	2.0	25
38	Looking for free riding: energy efficiency incentives and Italian homeowners. Energy Efficiency, 2014, 7, 571-590.	2.8	33
39	Stated choices and benefit estimates in the context of traffic calming schemes: Utility maximization, regret minimization, or both?. Transportation Research, Part A: Policy and Practice, 2014, 61, 121-135.	4.2	33
40	The value of water quality improvements in the region Berlinâ€"Brandenburg as a function of distance and state residency. Water Resources and Economics, 2014, 5, 49-66.	2.2	32
41	Trading off dietary choices, physical exercise and cardiovascular disease risks. Social Science and Medicine, 2013, 93, 130-138.	3.8	13
42	The role of regret minimisation in lifestyle choices affecting the risk of coronary heart disease. Journal of Health Economics, 2013, 32, 253-260.	2.7	36
43	Tools for Modelling and Assessing Peri-Urban Land Use Futures. , 2013, , 69-88.		1
44	Site choices in recreational demand: a matter of utility maximization or regret minimization?. Journal of Environmental Economics and Policy, 2012, 1, 32-47.	2.5	27
45	Random Regret Minimization: Exploration of a New Choice Model for Environmental and Resource Economics. Environmental and Resource Economics, 2012, 51, 413-429.	3.2	59
46	Considerations Around Coding the Membership Probability Function in a Latent Class Analysis: Renewed Insights. Pharmacoeconomics, 0, , .	3.3	0